One of the major mechanisms by which thalidomide exerts its anti-angiogenic effects is the suppression of vascular endothelial growth factor (VEGF), leading to the inhibition of new blood vessel formation and the suppression of tumor growth and inflammation [9]. Here, VEGFA is linked to neoplasm.